Buscar recursos académicos

BackgroundThe use of antibiotics may influence the efficacy and toxicity of immune checkpoint inhibitors (ICIs) by altering the gut microbiota. However, current evidence on the link between antibiotic use and immune-rela...

BackgroundThe prevalence of type 2 diabetes is continuously increasing, and optimizing the treatment strategies for diabetes is an important clinical issue. SGLT2 inhibitors (SGLT2i) and DPP-4 inhibitors (DPP-4i) are two...

BackgroundThe toxicities associated with immune checkpoint inhibitors (ICIs) can affect nearly all organ systems. Although previous studies have examined specific types of immune-related adverse events (irAEs) associated...

ObjectivesTo conduct a scoping review mapping the extent, nature, and consistency of available evidence regarding the effects of sodium–glucose cotransporter-2 (SGLT2) inhibitors on kidney function, proteinuria, kidney...

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPis) are the standard of care for primary ovarian cancer (OC), yet adverse events (AEs) frequently necessitate dose modifications. The prognostic impact of ...

Abstract Background Current guidelines recommend baseline insulin as the standard treatment for most people hospitalised with type 2 diabetes (PWT2D). However, they generally discourage the use of sodium–glucose cotran...

ObjectiveTo systematically evaluate the incidence of tuberculosis (TB) in cancer patients treated with immune checkpoint inhibitors (ICIs) and compare the risk of TB between ICI-treated and non-ICI-treated cancer patient...

Abstract Poly (ADP-ribose) polymerase-1 (PARP-1) is an enzyme that plays a pivotal role in DNA repair and the maintenance of genomic stability. The discovery of synthetic lethality in tumors with homologous recombination...

ObjectiveThe impact of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) on postoperative atrial fibrillation (AF) recurrence and cardiac function in patients with AF and heart failure (HF) undergoing catheter ablation ...

Janus kinase (JAK) inhibitors represent a major advancement in the management of immune-mediated inflammatory diseases. A balanced approach that carefully weighs therapeutic benefits against potential risks is essential....

Materias / palabras clave: cancer; immune checkpoint inhibitors; incidence; morbidity risk; tuberculosis

Materias / palabras clave: advanced breast cancer; CDK4/6 inhibitors; ctDNA; endocrine therapy; overall survival; treatment sequencing

Abstract The abnormal formation of the membrane attack complex (MAC) is intrinsically linked to a range of acute and chronic immune diseases. The insertion of complement C9 into the membrane is the final step and kinetic...

The effects of different concentrations of biological nitrification inhibitors(methyl p-hydroxyphenylpropionate(MHPP), syringic acid(SA)) and chemical nitrification inhibitors(dicyanediamine(DCD), 3, 4- dimethyl-1H-pyraz...

Abstract Immune checkpoint inhibitors (ICI) have transformed the treatment of metastatic malignancies, yet only 20–40% of unselected patients benefit. Peripheral blood could offer a minimally invasive and dynamic sourc...

Abstract Glucocorticoid (GC) use in rheumatoid arthritis (RA) remains concerning due to adverse effects. Janus kinase inhibitors (JAKi) may enable GC reduction or discontinuation. This study examined factors associated w...

Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood. Early immune checkpoint inhibitors hav...

Background: Leukemia is the most common childhood cancer. While tyrosine kinase inhibitors (TKIs) improve survival, they impose substantial economic burdens. This study evaluates the impact of China’s National Volume-B...

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cholinergic dysfunction, making acetylcholinesterase (AChE) a key therapeutic target. Although Garcinia kola has been widely reported ...

Abstract Background Axial spondyloarthritis (axSpA) is commonly treated with tumor necrosis factor-alpha (TNF-α) inhibitors, which show good efficacy but may cause adverse effects or lose effectiveness over time. Interl...

Atherosclerosis, driven by elevated cholesterol levels, remains a major risk factor for cardiovascular disease. 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the rate-limiting enzyme involved in cholesterol bio...

BackgroundImmune checkpoint inhibitors (ICIs) have markedly improved outcomes in metastatic microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) gastrointestinal (GI) malignancies. However, in frag...

BackgroundDown syndrome (DS) is associated with chronic hyperactivation of interferon signaling and downstream Janus kinase (JAK) and STAT pathways, contributing to increased susceptibility to autoimmunity, autoinflammat...

Key Points. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were associated with lower nephrolithiasis risk compared with dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in patients with...